Alimera Sciences Inc

Alimera Sciences — Q3 2016 Earnings Presentation

12 slides from Alimera Sciences's earnings presentation, Nov 3, 2016

  1. Slide 1: Third Quarter 2016 Results Conference Call

    Third Quarter 2016 Results Conference Call Thursday, November 3, 2016 Exhibit 99.2

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, the opportunity growth potential of ILUVEN, the adoption of reimbursement coding in the Middle East, the market si

  3. Slide 3: Highlights

    © 2016 Alimera Sciences, Inc., All Rights Reserved 3 Highlights Overall Revenue Growth 3Q15 3Q16 $8.3M $6.9M +20% • Grew revenues year over year, both in the US and international • Significant progress in obtaining reimbursement in new markets • Strengthened balanced sheet • Amended term loan with H

  4. Slide 4: Real World Evidence - Europe

    © 2016 Alimera Sciences, Inc., All Rights Reserved 4 Real World Evidence - Europe Location N° of eyes (pts) Follow-up Medisoft 2nd data extract results (13 sites in the UK)1 290 Eyes (258 pts) Up to 722 days IRISS 2nd data extract (37 sites in UK, DE, PT)2 328 Eyes (292 pts) Up to 763 days 1. Bailey

  5. Slide 5: United States Continued Growth and Continued Account Penetration

    © 2016 Alimera Sciences, Inc., All Rights Reserved 5 United States Continued Growth and Continued Account Penetration 3Q15 3Q16 $6.2M $5.0M +24% U.S. Revenue Growth Two of Three Strongest Sales Months August and September 2016 were two of our three strongest sales months in the United States. Added

  6. Slide 6: Europe Continued Progress

    © 2016 Alimera Sciences, Inc., All Rights Reserved 6 Europe Continued Progress 3Q15 3Q16 $2.1M $1.9M +11% European Revenue Growth Germany Sixth consecutive quarter of unit volume growth, a record high in terms of ILUVIEN implants sold, despite seasonality UK Initiating discussions 4Q16 to amend reim

  7. Slide 7: Expanding International Footprint

    © 2016 Alimera Sciences, Inc., All Rights Reserved 7 Expanding International Footprint Middle East Recently announced first sales and usage of ILUVIEN under agreement with MEAgate. Ireland Pricing approved in July Italy Distribution partner SIFI is in active discussions regarding pricing anticipate

  8. Slide 8: Financial Overview

    Financial Overview Rick Eiswirth, President & CFO

  9. Slide 9: Select Income Statement Data

    © 2016 Alimera Sciences, Inc., All Rights Reserved 9 Select Income Statement Data ($000’s) Three Months Ended September 30, 2016 Unaudited Results Three Months Ended September 30, 2015 Unaudited Results Revenue $8,298 $6,901 Gross Profit $7,812 $6,267 Gross Margin 94.1% 90.8% Net (Loss) From Operati

  10. Slide 10: Select Balance Sheet Data

    © 2016 Alimera Sciences, Inc., All Rights Reserved 10 Select Balance Sheet Data ($000’s) As of September 30, 2016 Unaudited Results As of December 31, 2015 Cash & Cash Equivalents $33,853 $31,075 Total Current Assets $51,603 $45,159 Total Assets $74,980 $70,484 Total Current Liabilities $42,678 $39,

  11. Slide 11: Closing Remarks

    Closing Remarks Dan Myers, CEO

  12. Slide 12: Third Quarter 2016 Results Conference Call

    Third Quarter 2016 Results Conference Call Thursday, November 3, 2016

Alimera Sciences — Q3 2016 Earnings Presentation on 6ix